Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

30.01.19	Novartis erzielt 2018 ein kräftiges Umsatzwachstum bei gleichzeitiger Steigerung der Kerngewinnmarge, baut wegweisende Therapie¬plattformen auf und fokussiert das Unternehmen (GlobeNewswire)
08.01.19	Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease (GlobeNewswire)
07.01.19	Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder (GlobeNewswire)
21.12.18	Novartis successfully completes acquisition of Endocyte (GlobeNewswire)
20.12.18	Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies (GlobeNewswire)
20.12.18	Novartis announces new CEO of Oncology Business Unit (GlobeNewswire)
19.12.18	Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises (GlobeNewswire)
19.12.18	Alcon Announces Acquisition of Tear Film Innovations, Inc. (GlobeNewswire)
13.12.18	Novartis receives European Commission approval for self-administration of Xolair® across all indications (GlobeNewswire)
10.12.18	Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder (GlobeNewswire)
08.12.18	Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease (GlobeNewswire)
06.12.18	Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses (GlobeNewswire)
03.12.18	Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1 (GlobeNewswire)
02.12.18	Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies (GlobeNewswire)
01.12.18	Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers (GlobeNewswire)
01.12.18	Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program (GlobeNewswire)
29.11.18	Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe (GlobeNewswire)
27.11.18	Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim) (GlobeNewswire)
27.11.18	Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London (GlobeNewswire)
23.11.18	Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease (GlobeNewswire)
20.11.18	Novartis rises to second place in 2018 Access to Medicine Index (GlobeNewswire)
16.11.18	FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication (GlobeNewswire)
16.11.18	Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer (GlobeNewswire)
13.11.18	Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London (GlobeNewswire)
11.11.18	New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients (GlobeNewswire)
05.11.18	Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms (GlobeNewswire)
02.11.18	Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs (GlobeNewswire)
02.11.18	Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology (GlobeNewswire)
31.10.18	Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz) (GlobeNewswire)
29.10.18	Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH (GlobeNewswire)
27.10.18	Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD (GlobeNewswire)
26.10.18	Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis (GlobeNewswire)
23.10.18	Alcon to develop SMART Suite digital health platform for cataract surgery (GlobeNewswire)
23.10.18	Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed (GlobeNewswire)
22.10.18	Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma (GlobeNewswire)
20.10.18	Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone (GlobeNewswire)
19.10.18	Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC (GlobeNewswire)
19.10.18	Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden (GlobeNewswire)
18.10.18	Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms (GlobeNewswire)
18.10.18	Novartis erzielt im dritten Quartal starkes Wachstum und treibt Innovationen wie fortschrittlicheTherapieplattformen voran, um das zukünftige Wachstum zu beschleunigen (GlobeNewswire)
18.10.18	Novartis erzielt im dritten Quartal starkes Wachstum und treibt Innovationen wie fortschrittlicheTherapieplattformen voran, um das zukünftige Wachstum zu beschleunigen (GlobeNewswire)
18.10.18	Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth (GlobeNewswire)
16.10.18	Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis (GlobeNewswire)
11.10.18	Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access (GlobeNewswire)
10.10.18	Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis (GlobeNewswire)
10.10.18	Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden (GlobeNewswire)
09.10.18	Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study (GlobeNewswire)
08.10.18	Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients (GlobeNewswire)
04.10.18	Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges (GlobeNewswire)
03.10.18	Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20:03		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
18:01		Börse New York in Grün: So steht der NASDAQ 100 aktuell
18:01		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
17:58		Handel in Europa: STOXX 50 schliesst im Minus
17:58		Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels
17:58		SPI-Handel aktuell: SPI zum Handelsende leichter
17:58		Schwacher Handel: SMI schliesst mit Verlusten
17:58		Verluste in Europa: Euro STOXX 50 letztendlich leichter